Eloxatin Adds Adjuvant Colorectal Cancer Claim Based On Disease-Free Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' agent is the first oncologic to be approved for an adjuvant colorectal cancer indication based on a disease-free survival endpoint. It did not demonstrate benefit in overall survival after a median follow-up of four years.